Hostname: page-component-848d4c4894-8bljj Total loading time: 0 Render date: 2024-06-15T17:05:35.807Z Has data issue: false hasContentIssue false
  • English
  • Français

The Complex Cancer Care Coverage Environment — What is the Role of Legislation?

A Case Study from Massachusetts

Published online by Cambridge University Press:  01 January 2021

Christine Leopold ,
Rebecca L. Haffajee ,
Christine Y. Lu  and
Anita K. Wagner
Get access Rights & Permissions [Opens in a new window]

Abstract

Over the past decades, anti-cancer treatments have evolved rapidly from cytotoxic chemotherapies to targeted therapies including oral targeted medications and injectable immunooncology and cell therapies. New anti-cancer medications come to markets at increasingly high prices, and health insurance coverage is crucial for patient access to these therapies. State laws are intended to facilitate insurance coverage of anti-cancer therapies.

Using Massachusetts as a case study, we identified five current cancer coverage state laws and interviewed experts on their perceptions of the relevance of the laws and how well they meet the current needs of cancer care given rapid changes in therapies. Interviewees emphasized that cancer therapies, as compared to many other therapeutic areas, are unique because insurance legislation targets their coverage. They identified the oral chemotherapy parity law as contributing to increasing treatment costs in commercial insurance. For commercial insurers, coverage mandates combined with the realities of new cancer medications — including high prices and often limited evidence of efficacy at approval — compound a difficult situation. Respondents recommended policy approaches to address this challenging coverage environment, including the implementation of closed formularies, the use of cost-effectiveness studies to guide coverage decisions, and the application of value-based pricing concepts. Given the evolution of cancer therapeutics, it may be time to evaluate the benefits and challenges of cancer coverage mandates.

Type
Independent Articles
Information
Journal of Law, Medicine & Ethics , Volume 48 , Issue 3: A Bold Agenda for the Next Steps in Health Reform , Fall 2020 , pp. 538 - 551
Copyright
Copyright © American Society of Law, Medicine and Ethics 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Cancer Society, Cancer Facts & Figures 2018 (Atlanta: American Cancer Society; 2018) at 76, available at <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-andfigures/2018/cancer-facts-and-figures-2018.pdf> (last visited August 7, 2020).+(last+visited+August+7,+2020).>Google Scholar
IQIVA Institute, , Global Oncology Trends 2019: Therapeutics, Clinical Development and Health System Implications, May 2019, available at <https://www.iqvia.com/institute/reports/global-oncology-trends-2019> (last visited August 7, 2020).+(last+visited+August+7,+2020).>Google Scholar
Chen, E.Y., Raghunathan, V., and Prasad, V., “An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate,” An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate, 79, no. 7 (2019): 915–921; Darrow, J.J., Avorn, J., and Kesselheim, A.S., “Approval, FD. and Regulation of Pharmaceuticals, 1983-2018,” JAMA 323, no. 2 (2020): 164-176.Google Scholar
Gyawali, B., Hey, S.P., and Kesselheim, A.S., “Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval,” Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, 179, no. 7 (2019): 906–913.Google Scholar
Redberg, R.F., “Faster Drug Approvals Are Not Always Better and Can Be Worse,” JAMA Internal Medicine 175, no. 8 (2015):1398–1398, available at <https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2323409> (last visited August 10, 2020).CrossRefGoogle Scholar
Pregelj, L., Hwang, T.J., Hine, D.C., Siegel, E.B., Barnard, R.T., Darrow, J.J., et al., “Precision Medicines Have Faster Approvals Based On Fewer And Smaller Trials Than Other Medicines,” Health Affairs Project HOPE 37, no. 5 (2018): 724–731.CrossRefGoogle ScholarPubMed
Hwang, T.J., Franklin, J.M., Che, C.T., Lauffenburger, J.C., Gyawali, B., Kesselheim, A.S., et al., “Efficacy, Safety, and Regulatory Approval of Food and Drug Administration-Designated Breakthrough and Non-breakthrough Cancer Medicines,” Journal of Clinical Oncology 36, no. 18 (2018): 1805–1812.CrossRefGoogle ScholarPubMed
Naci, H., Smalley, K.R., and Kesselheim, A.S., “Characteristics of Preapproval and Post-approval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration,” JAMA 318, no. 7 (2017): 626–636, available at <https://jamanetwork.com/journals/jama/fullarticle/2648631> (last visited August 10, 2020).CrossRefGoogle Scholar
Peppercorn, J., “Financial Toxicity and Societal Costs of Cancer Care: Distinct Problems Require Distinct Solutions,” The Oncologist 22, no. 2 (2017): 123–125, available at <https://theoncologist.alphamedpress.org/lookup/doi/10.1634/theoncologist.2016-0301> (last visited August 10, 2020).CrossRefGoogle ScholarPubMed
Dusetzina, S.B., Conti, R.M., Yu, N.L., and Bach, P.B., “Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending,” JAMA Internal Medicine 177, no. 8 (2017): 1185–1188.CrossRefGoogle ScholarPubMed
Bestvina, C.M., Zullig, L.L., and Zafar, S.Y., “The Implications of Out-of-Pocket Cost of Cancer Treatment in the USA: A Critical Appraisal of the Literature,” Future Oncology 10, no. 14 (2014): 2189–2199, available at <http://www.futuremedicine.com/doi/abs/10.2217/fon.14.130> (last visited August 10, 2020).CrossRefGoogle ScholarPubMed
American Society of Clinical Oncology, “Reimbursement for cancer treatment: coverage of off-label drug indications,” Journal of Clinical Oncology 24, no. 19 (2006): 3206–3208.CrossRefGoogle Scholar
Kircher, S.M., Meeker, C.R., Nimeiri, H., Geynisman, D.M., Zafar, S.Y., Shankaran, V., et al., The Parity Paradigm: Can Legislation Help Reduce the Cost Burden of Oral Anticancer Medications? Value Health 19, no. 1 (2016): 88–98, available at <http://linkinghub.elsevier.com/retrieve/pii/S1098301515050780> (last visited August27, 2020).+(last+visited+August27,+2020).>Google Scholar
Brooks, G.A., Hoverman, J.R., and Colla, C.H., “The Affordable Care Act and Cancer Care Delivery,” The Affordable Care Act and Cancer Care Delivery, 23, no. 3 (2017): 163–167, available at <https://journals.lww.com/journalppo/fulltext/2017/05000/The_Affordable_Care_Act_and_Cancer_Care_Delivery.3.aspx> (last visited August 10, 2020); Han, X. and Jemal, A., “The Affordable Care Act and Cancer Care for Young Adults,” Cancer Journal 23, no. 3 (2017): 194-198, available at <https://journals.lww.com/journalppo/fulltext/2017/05000/The_Affordable_Care_Act_and_Cancer_Care_for_Young.8.aspx> (last visited August 10, 2020); Leopold, C., Park, E.R., and Nekhlyudov, L., “The Impact of the Affordable Care Act on Cancer Survivorship,” Cancer Journal 23, no. 3 (2017): 181–189.Google Scholar
Alvarez, E.M., Keegan, T.H., Johnston, E.E., Haile, R., Sanders, L., Wise, P.H., et al., “The Patient Protection and Affordable Care Act Dependent Coverage Expansion: Disparities in Impact among Young Adult Oncology Patients,” Cancer 124, no. 1 (2018): 110–117, available at <http://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.30978> (last visited August 10, 2020); Chino, F., Suneja, G., Moss, H., Zafar, S.Y., Havrilesky, L., and Chino, J., “Health Care Disparities in Cancer Patients Receiving Radiation: Changes in Insurance Status After Medicaid Expansion Under the Affordable Care Act,” International Journal of Radiation Oncology*Biology*Physics 101, no. 1 (2018): 9–20, available at <http://www.sciencedirect.com/science/article/pii/S0360301617341883> (last visited August 10, 2020); Eguia, E., Cobb, A.N., Kothari, A.N., Molefe, A., Afshar, M., Aranha, G.V., et al., “Impact of the Affordable Care Act (ACA) Medicaid Expansion on Cancer Admissions and Surgeries,” Annals of Surgery 268, no. 4 (2018): 584-590, available at <http://Insights.ovid.com/crossref?an=00000658-201810000-00006> (last visited August 10, 2020); Hendryx, M. and Luo, J., “Increased Cancer Screening for Low-income Adults Under the Affordable Care Act Medicaid Expansion,” Medical Care 56, no. 11 (2018): 944-949; Jemal, A., Lin, C.C., Davidoff, A.J., and Han, X., “Changes in Insurance Coverage and Stage at Diagnosis Among Nonelderly Patients With Cancer After the Affordable Care Act,” Journal of Clinical Oncology 35, no. 35 (2017): 3906–3915, available at <http://ascopubs.org/doi/full/10.1200/JCO.2017.73.7817> (last visited August 10, 2020).CrossRefGoogle ScholarPubMed
Davidoff, A.J., Guy, G.P., Hu, X., Gonzales, F., Han, X., Zheng, Z., et al., “Changes in Health Insurance Coverage Associated With the Affordable Care Act Among Adults With and Without a Cancer History: Population-based National Estimates,” Medical Care 56, no. 3 (2018): 220–227, available at <http://Insights.ovid.com/crossref?an=00005650-201803000-00005> (last visited August 10, 2020); Dixon, M.S., Cole, A.L, and Dusetzina, S.B., “Out-of-Pocket Spending Under the Affordable Care Act for Patients With Cancer,” Cancer Journal 23, no. 3 (2017): 175–180; Shih, Y-CT., Xu, Y., Liu, L., and Smieliauskas, F., “Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries,” Journal Clinical Oncology 35, no. 22 (2017): 2482–2489, available at <http://ascopubs.org/doi/full/10.1200/JCO.2017.72.3742> (last visited August 10, 2020).CrossRefGoogle ScholarPubMed
“The Policy, Politics and Law of Cancer,” The Solomon Center for Health Law and Policy at Yale Law School, 2018, available at <https://law.yale.edu/solomon-center/events/policy-politics-and-law-cancer/conference-videos> (last visited August 10, 2020).+(last+visited+August+10,+2020).>Google Scholar
Ritchie, J., Lu, C., Williams, K., and Day, R., “Sample Size is Beside the Point in Policy Development Research,” Australian and New Zealand Journal of Public Health 29, no. 6 (2005): 583, PMID:16366072; Patton, M.Q., Qualitative Research and Evaluation Methods, Third edition (Newbury Park, CA: Sage Publications, 2002).CrossRefGoogle ScholarPubMed
Malterud, K., Siersma, V.D., and Guassora, A.D., “Sample Size in Qualitative Interview Studies: Guided by Information Power,” Qualitative Health Research 26 (2016): 1753–1760.CrossRefGoogle ScholarPubMed
Cho, J.Y. and Lee, E.H., “Reducing Confusion about Grounded Theory and Qualitative Content Analysis: Similarities and Differences,” The Qualitative Report 19, no. 32 (2014); Mayring, P., “Qualitative Content Analysis,” Forum: Qualitative Social Research 20, no. 3 (2010).Google Scholar
Brown Bagging versus White Bagging, Value-Based Cancer Care, 2013, available at <http://www.valuebasedcancer.com/issue-archive/2013/july-2013-vol-4-no-6/vbcc-13047/> (last visited August 10, 2020).+(last+visited+August+10,+2020).>Google Scholar
See Brown Bagging versus White Bagging, supra note 21; White and Brown Bagging Emerging Practices, Emerging Regulation (Mount Prospect, IL: The National Association of Boards of Pharmacy; 2018) available at <https://nabp.pharmacy/wp-content/uploads/2018/04/White-Bagging-and-Brown-Bagging-Report-2018_Final.pdf> (last visit August 10, 2020).+(last+visit+August+10,+2020).>Google Scholar
See Brown Bagging versus White Bagging, supra note 21; “Senate Oks Long-Sought Study on Insurer ‘Bagging,’” Massachusetts Health and Hospital Association, 2017, available at <https://www.mhalink.org/MHA/MyMHA/Communications/MondayReportItems/Content/2017/05-29/Items/SENATE_OKs_LONG-SOUGHT_STUDY.aspx> (last visited August 10, 2020).+(last+visited+August+10,+2020).>Google Scholar
Trends, Charts, and Maps, ClinicalTrials.gov, 2019, available at <https://clinicaltrials.gov/ct2/resources/trends> (last visited August 10, 2020).+(last+visited+August+10,+2020).>Google Scholar
Darrow, J. et al., “New FDA Breakthrough-Drug Category — Implications for Patients,” New England Journal of Medicine 370 (2014): 1252–1258, available at <https://www.nejm.org/doi/10.1056/NEJMhle1311493?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dwww.ncbi.nlm.nih.gov> (last visited August 10, 2020).CrossRefGoogle ScholarPubMed
See Chen et al., supra note 3; Darrow, supra note 3; see Gyawali, supra note 4; Redberg, supra note 5; Pregelj, supra note 6; Hwang, supra note 7.Google Scholar
Naci, H., Davis, C., Savovi, J., Higgins, J.P.T., Sterne, J.A.C., Gyawali, B., et al., “Design Characteristics, Risk of Bias, and Reporting of Randomised Controlled Trials Supporting Approvals of Cancer Drugs by European Medicines Agency, 2014-16: Cross Sectional Analysis,” BMJ 5221 (2019); Davis, C., Naci, H., Gurpinar, E., et al., “Availability of Evidence of Benefits on Overall Survival and Quality of Life of Cancer Drugs Approved by European Medicines Agency: Retrospective Cohort Study of Drug Approvals 2009-13,” BMJ 359 (2017): j4530; Hwang, T.J. and Gyawali, B., “Association Between Progression Free Survival and Patients’ Quality of Life in Cancer Clinical Trials,” International Journal of Cancer 144, no. 7 (2019): 1746–1751; Kovic, B., Jin, X., Kennedy, S.A., et al., “Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology: A Systematic Review and Quantitative Analysis,” JAMA Internal Medicine 178, no. 12 (2018): 1586-1596.Google Scholar
Lombardi, P., Marandino, L., Luca, E. D., et al., “Quality of Life Assessment and Reporting in Colorectal Cancer: A Systematic Review of Phase III Trials Published Between 2012 and 2018,” Critical Reviews in Oncology/Hematology 146 (2020).CrossRefGoogle ScholarPubMed
Bennette, C.S., Richards, C., Sullivan, S.D., and Ramsey, S.D., “Steady Increase In Prices For Oral Anticancer Drugs After Market Launch Suggests A Lack Of Competitive Pressure,” Health Affairs 35, no. 5 (2016): 805–812, available at <http://content.healthaffairs.org/cgi/doi/10.1377/hlthaff.2015.1145> (last visited August 10, 2020); “US Cancer Drug Costs Increasing Despite Competition,” ScienceDaily, available at <https://www.sciencedaily.com/releases/2017/10/171031120329.htm> (last visited August 10, 2020); R.Conti, M., Fein, A.J., and Bhatta, S.S., “National Trends In Spending On And Use Of Oral Oncologics, First Quarter 2006 Through Third Quarter 2011,” Health Affairs 33, no. 10 (2014): 1721–1727, available at <https://www-healthaffairs-org.ezp-prod1.hul.harvard.edu/doi/abs/10.1377/hlthaff.2014.0001> (last visited August 10, 2020); Shih, Y-CT., Smieliauskas, F., Geynisman, D.M., Kelly, R.J., and Smith, T.J., “Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011,” Journal of Clinical Oncology 33, no. 19 (2015): 2190–2196; available at <http://ascopubs.org.ezp-prod1.hul.harvard.edu/doi/abs/10.1200/JCO.2014.58.2320> (last visited August 10, 2020).CrossRefGoogle ScholarPubMed
Smith, S.K., Nicolla, J., and Zafar, S.Y., “Bridging the Gap Between Financial Distress and Available Resources for Patients With Cancer: A Qualitative Study,” Journal of Oncology Practice 10, no. 5 (2014): e368–e372, available at <http://ascopubs.org/doi/10.1200/JOP.2013.001342> (last visited August 10, 2020); Chino, F., Peppercorn, J.M., Rushing, C., Kamal, A.H., Altomare, I., Samsa, G., et al., “Out-of-Pocket Costs, Financial Distress, and Underinsurance in Cancer Care,” JAMA Oncology 3, no. 11 (2017): 1582-1584; Lathan, C.S., Cronin, A., Tucker-Seeley, R., Zafar, S.Y., Ayanian, J.Z., and Schrag, D., “Association of Financial Strain With Symptom Burden and Quality of Life for Patients With Lung or Colorectal Cancer,” Journal of Clinical Oncology 34, no. 15 (2016): 1732– 1740, available at <http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.63.2232> (last visited August 10, 2020); Emanuel, E., “We Can't Afford the Drugs That Could Cure Cancer,” Wall Street Journal, September 20, 2018, available at <https://www.wsj.com/articles/we-cant-afford-the-drugs-that-couldcure-cancer-1537457740> (last visited August 10, 2020).CrossRefGoogle ScholarPubMed
Prescription Medications Account For One In Four Dollars Spent By A Commercial Health Plan, Health Affairs, available at <https://www.healthaffairs.org/do/10.1377/hblog20180821.820628/full/> (last visited August 11, 2020).+(last+visited+August+11,+2020).>Google Scholar
Runyan, A., Banks, J., and Bruni, D.S., “Current and Future Oncology Management in the United States,” Journal Managed Care & Specialty Pharmacy 25, no. 2 (2019): 272–281, available at <https://www.jmcp.org/doi/10.18553/jmcp.2019.25.2.272> (last visited August 11, 2020).CrossRefGoogle ScholarPubMed
Morgan, S.G., Bathula, H.S., and Moon, S., “Pricing of Pharmaceuticals is Becoming a Major Challenge for Health Systems,” BMJ 368 (2020).Google Scholar
Sarpatwari, A. and Kesselheim, A.S., “Tepid Steps on Drug Pricing,” JAMA Internal Medicine 179, no. 3 (2019): 439–441, available at <https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2720751> (last visited August 11, 2020).CrossRefGoogle ScholarPubMed
Ramsey, S.D., “How State and Federal Policies as Well as Advances in Genome Science Contribute to the High Cost of Cancer Drugs,” Health Affairs 34, no. 4 (2015): 571–575.CrossRefGoogle ScholarPubMed
Leopold, C., Peppercorn, J.M., Zafar, S.Y., and Wagner, A.K., “Defining Value of Cancer Therapeutics-A Health System Perspective,” Journal of the National Cancer Institute 110, no. 7 (2018): 699–703.CrossRefGoogle ScholarPubMed
Drug Affordability Review Board Legislation, NASHP, available at <https://www.nashp.org/comparison-of-bills-creatingstate-prescription-drug-affordability-review-boards/> (last visited August 27, 2020).+(last+visited+August+27,+2020).>Google Scholar
Maryland's Path to a Prescription Drug Affordability Board, Families USA, 2019, available at <https://familiesusa.org/blog/2019/07/maryland%E2%80%99s-path-prescriptiondrug-affordability-board> (last visited August 11, 2020). (last visited August 11, 2020).' href=https://scholar.google.com/scholar?q=Maryland's+Path+to+a+Prescription+Drug+Affordability+Board,+Families+USA,+2019,+available+at++(last+visited+August+11,+2020).>Google Scholar
“Prescription-Drug Coupons — No Such Thing as a Free Lunch,” NEJM 369, no. 13 (2013), available at <https://www-nejm-org.ezp-prod1.hul.harvard.edu/doi/full/10.1056/NEJMp1301993?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed> (last visited August 10, 2020).+(last+visited+August+10,+2020).>Google Scholar
Malterud et al., supra note 19.Google Scholar